Mr Patrick Heron

KANDO id: 12780

Bio

Mr. Heron is a General Partner in the Menlo Park Office and joined Frazier Healthcare in 1999. He focuses on early and late-stage private and public biotechnology and specialty pharmaceutical investments. He has been active in forming companies and founding investments including Marcadia Biotech (sold to Roche in 2010), a diabetes and obesity company, Calixa (sold to Cubist in 2009), Cerexa (sold to Forest in 2007), both anti-infectives companies; and Trubion Pharmaceuticals, next generation antibody therapeutics (sold to Emergent BioSolutions in 2010). In specialty pharmaceuticals, he led Frazier’s involvement in a respiratory company, MedPointe (sold to Meda AB in 2007). He is currently on the boards of Collegium, Kalidex, Precision Dermatology, QuatRx, Silvergate, Tobira and VentiRx. Prior to joining Frazier Healthcare, Mr. Heron helped develop McKinsey & Co.'s West Coast biotechnology consulting practice. His projects included mergers and acquisitions, product launch, sales force optimization, corporate partnering and research prioritization. He was a Phi Beta Kappa graduate and Morehead Scholar at the University of North Carolina at Chapel Hill and holds an M.B.A. from Harvard Business School.


Career


Frazier Healthcare Ventures

Investment firm providing growth and venture capital to healthcare companies.
Email: [email protected]

McKinsey & Co

Global management consulting firm.
N/A (past)

Education